Subscribe
olm26250-istockphoto-com-patent-2-1-
olm26250 / iStockphoto.com
28 March 2019Big Pharma

Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers

The UK Supreme Court’s  decision in Actavis v Eli Lilly  confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle